Correction: The Relative Contribution of Metabolic and Structural Abnormalities to Diastolic Dysfunction in Obesity (International Journal of Obesity, (2018), 42, 3, (441-447), 10.1038/ijo.2017.239);The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity

International Journal of Obesity

Volumn 42, Issue 3, 2018, Pages 441-447

  Rayner, J J ^a   Banerjee, R ^a   Holloway, C J ^a   Lewis, A J M ^a   Peterzan, M A ^a   Francis, J M ^a   Neubauer, S ^a   Rider, O J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FAT MASS; FEMALE; GEOMETRY; GLUCOSE LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN LEVEL; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL LEVEL; BLOOD; DIAGNOSTIC IMAGING; DIASTOLE; HEART LEFT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BODY MASS INDEX; COHORT STUDIES; DIASTOLE; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; MAGNETIC RESONANCE IMAGING; MALE; OBESITY; TRIGLYCERIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85044528429     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/s41366-019-0404-2     Document Type: Erratum

References (52)

1. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
2. Alpert MA, Terry BE, Mulekar M, Cohen MV, Massey CV, Fan TM et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 1997; 80: 736-740.
3. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 320-332.
4. Powell BD, Redfield MM, Bybee KA, Freeman WK, Rihal CS. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J Cardiol 2006; 98: 116-120.
5. Rider OJ, Francis JM, Ali MK, Byrne J, Clarke K, Neubauer S et al. Determinants of left ventricular mass in obesity; a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2009; 11: 9.
6. Alexander JK. Obesity and cardiac performance. Am J Cardiol 1964; 14: 860-865.
7. Kaltman AJ, Goldring RM. Role of circulatory congestion in the cardiorespiratory failure of obesity. Am J Med 1976; 60: 645-653.
8. Otto ME, Belohlavek M, Khandheria B, Gilman G, Svatikova A, Somers V. Comparison of right and left ventricular function in obese and nonobese men. Am J Cardiol 2004; 93: 1569-1572.
9. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B et al. Alterations in left ventricular structure and function in young healthy obese women: Assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004; 43: 1399-1404.
10. Rider OJ, Francis JM, Ali MK, Petersen SE, Robinson M, Robson MD et al. Beneficial cardiovascular effects of bariatric surgical and dietary weight loss in obesity. J Am Coll Cardiol 2009; 54: 718-726.
11. Rider OJ, Francis JM, Ali MK, Holloway C, Pegg T, Robson MD et al. Effects of catecholamine stress on diastolic function and myocardial energetics in obesity. Circulation 2012; 125: 1511-1519.
12. Pascual M, Pascual DA, Soria F, Vicente T, Hernandez AM, Tebar FJ et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart 2003; 89: 1152-1156.
13. Kossaify A, Nicolas N. Impact of overweight and obesity on left ventricular diastolic function and value of tissue Doppler echocardiography. Clin Med Insights Cardiol 2013; 7: 43-50.
14. Eaton CB, Pettinger M, Rossouw J, Martin LW, Foraker R, Quddus A et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail 2016; 9: pii: e002883.
15. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging 2013; 29: 1043-1050.
16. Rider OJ, Lewandowski A, Nethononda R, Petersen SE, Francis JM, Pitcher A et al. Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging. Eur Heart J 2013; 34: 292-299.
17. Banerjee R, Rial B, Holloway CJ, Lewandowski AJ, Robson MD, Osuchukwu C et al. Evidence of a direct effect of myocardial steatosis on LV hypertrophy and diastolicdysfunction in adult and adolescent obesity. JACC Cardiovasc Imaging 2015; 8: 1468-1470.
18. Rider OJ, Cox P, Tyler D, Clarke K, Neubauer S. Myocardial substrate metabolism in obesity. Int J Obes (Lond) 2013; 37: 972-979.
19. Zeidan Z, Erbel R, Barkhausen J, Hunold P, Bartel T, Buck T. Analysis of global systolic and diastolic left ventricular performance using volume-time curves by real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2003; 16: 29-37.
20. Rider OJ, Banerjee R, Rayner JJ, Shah R, Murthy VL, Robson MD et al. Investigating a liver fat: Arterial stiffening pathway in adult and childhood obesity. Arterioscler Thromb Vasc Biol 2016; 36: 198-203.
21. Rial B, Robson MD, Neubauer S, Schneider JE. Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla. Magn Reson Med 2011; 66: 619-624.
22. Adamopoulos C, Meyer P, Desai RV, Karatzidou K, Ovalle F, White M et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: A propensity-matched study. Eur J Heart Fail 2011; 13: 200-206.
23. Levelt E, Rodgers CT, Clarke WT, Mahmod M, Ariga R, Francis JM et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J 2015; 65: 44-52.
24. Holloway CJ, Dass S, Suttie JJ, Rider OJ, Cox P, Cochlin LE et al. Exercise training in dilated cardiomyopathy improves rest and stress cardiac function without changes in cardiac high energy phosphate metabolism. Heart 2012; 98: 1083-1090.
25. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 2008; 40: 879-891.
26. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007; 356: 1140-1151.
27. Veech RL. The determination of the redox states and phosphorylation potential in living tissues and their relationship to metabolic control of disease phenotypes. Biochem Mol Biol Educ 2006; 34: 168-179.
28. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GR. Ketone bodies, potential therapeutic uses. IUBMB Life 2001; 51: 241-247.
29. Hue L, Taegtmeyer H. The Randle cycle revisited: A new head for an old hat. Am J Physiol-Endocrinol Metab 2009; 297: E578-E591.
30. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol-Heart Circulat Physiol 2000; 278: H1345-H1351.
31. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109: 2191-2196.
32. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome-an allostatic perspective. Biochim Biophys Acta 2010; 1801: 338-349.
33. Nelson MD, Victor RG, Szczepaniak EW, Simha V, Garg A, Szczepaniak LS. Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol 2013; 112: 1019-1024.
34. Schulze PC, Drosatos K, Goldberg IJ. Lipid use and misuse by the heart. Circ Res 2016; 118: 1736-1751.
35. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321: 225-236.
36. Alexander JK. Obesity and the heart. Heart Dis Stroke 1993; 2: 317-321.
37. Turkbey EB, McClelland RL, Kronmal RA, Burke GL, Bild DE, Tracy RP et al. The impact of obesity on the left ventricle: The Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc Imaging 2010; 3: 266-274.
38. Perego L, Pizzocri P, Corradi D, Maisano F, Paganelli M, Fiorina P et al. Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: A potential role for leptin in mediating human left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90: 4087-4093.
39. Rider OJ, Petersen SE, Francis JM, Ali MK, Hudsmith LE, Robinson MR et al. Ventricular hypertrophy and cavity dilatation in relation to body mass index in females with uncomplicated obesity. Heart 2011; 97: 203-208.
40. Purdham DM, Zou MX, Rajapurohitam V, Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 2004; 287: H2877-H2884.
41. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006; 69: 716-725.
42. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003; 93: 277-279.
43. Tajmir P, Ceddia RB, Li RK, Coe IR, Sweeney G. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase-and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 2004; 145: 1550-1555.
44. Abe Y, Ono K, Kawamura T, Wada H, Kita T, Shimatsu A et al. Leptin induces elongation of cardiac myocyte and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 2007; 292: H2387-H2396.
45. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res 2006; 72: 101-111.
46. Banks AS, Davis SM, Bates SH, Myers MG Jr. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000; 275: 14563-14572.
47. Ghilardi N, Skoda RC. The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol 1997; 11: 393-399.
48. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996; 93: 800-809.
49. Lee Y, Naseem RH, Duplomb L, Park BH, Garry DJ, Richardson JA et al. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci USA 2004; 101: 13624-13629.
50. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-1789.
51. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging 2012; 29: 1043-1050.
52. Utz W, Engeli S, Haufe S, Kast P, Bohnke J, Haas V et al. Moderate dietary weight loss reduces myocardial steatosis in obese and overweight women. Int J Cardiol 2012; 167: 905-909.